|
|
|
|
Vol. 62, Issue 2, 359-365, August 2002
Department of Clinical Pharmacology and Storr Liver Unit, University of Sydney, Westmead Millennium Institute, Westmead, New South Wales, Australia
| |
Abstract |
|---|
|
|
|---|
Cytochrome P450 3A4 (CYP3A4), the predominant P450 expressed in adult human liver, is both constitutively expressed and transcriptionally activated by a variety of structurally diverse xenochemicals. In this study, we examined the role of the constitutive androstane receptor (CAR), a member of the steroid/retinoid/thyroid hormone receptor superfamily, in the transcriptional regulation of CYP3A4. Herein, we demonstrate that CAR is capable of trans-activating expression of the CYP3A4 gene, both in vitro and in vivo. Induction of CYP3A4 is dependent on cooperativity between elements within the promoter proximal region of the gene and the distal xenobiotic-responsive enhancer module. CAR responsiveness was shown to be primarily mediated by two high-affinity binding motifs located within the CYP3A4 gene 5'-flanking region, approximately 7720 and 150 bases upstream of the transcription initiation site. Importantly, the human CAR response elements also mediate trans-activation of CYP3A4 by the human pregnane X receptor, suggesting that interplay between these receptors is likely to be an important determinant of CYP3A4 expression.
| |
Introduction |
|---|
|
|
|---|
The
cytochromes P450 (P450) are a superfamily of heme-thiolate-containing
proteins involved in the oxidative metabolism of a plethora of
endogenous and exogenous compounds (Nelson et al., 1996
). Cytochrome
P450 3A4 (CYP3A4), the predominant P450 isoform constitutively
expressed in adult human liver, is transcriptionally activated by a
variety of structurally diverse compounds, including rifampicin,
phenobarbital (PB), mifepristone, and clotrimazole (Maurel, 1996
).
trans-Activation of P450 genes by xenochemicals increases
the organism's capacity to metabolize and ultimately excrete toxins
and carcinogens (Denison and Whitlock, 1995
; Waxman, 1999
).
Until recently, the molecular mechanisms underlying the
transcriptional activation of the CYP3A4 gene were poorly
understood. A number of independent studies have demonstrated that the
human pregnane X receptor (hPXR) is activated by compounds that are known CYP3A4 inducers, including drugs, steroids, and
environmental chemicals (Bertilsson et al., 1998
; Blumberg et al.,
1998
; Lehmann et al., 1998
; Schuetz et al., 1998
). Ligand-activated
hPXR binds hormone response elements (HREs) in the 5'-flanking region
of the CYP3A4 gene as a heterodimer with the
9-cis retinoic acid receptor-
(RXR
) (Bertilsson et
al., 1998
; Blumberg et al., 1998
; Lehmann et al., 1998
; Goodwin et al.,
1999
). Targeted disruption of PXR in mice results in selective loss of
xenobiotic inducibility of the murine Cyp3a11 gene, but does
not affect constitutive expression in liver or intestine (Xie et al.,
2000a
; Staudinger et al., 2001
). Although PXR-RXR
heterodimers bind
an HRE in the promoter proximal region of CYP3A4 (prPXRE,
bases
172 to
149) (Bertilsson et al., 1998
; Blumberg et al., 1998
;
Lehmann et al., 1998
), activation of the native CYP3A4
promoter is dependent upon the presence of a distal
xenobiotic-responsive enhancer module (XREM, bases
7836 to
7208)
(Goodwin et al., 1999
). Cooperativity between promoter proximal and
distal PXR-response elements is central to the PXR-mediated trans-activation of CYP3A4.
Recently, Negishi and coworkers demonstrated that induction of
CYP2B genes by PB and a variety of structurally unrelated
compounds collectively known as "PB-like" inducers [e.g.,
chlorpromazine, methoxychlor, and
1,1,1-trichloro-1,2-bis(o,p'-chlorophenyl)ethane] was mediated by the constitutive androstane receptor (CAR) (Honkakoski et al., 1998
; Kawamoto et al., 1999
; Sueyoshi et al., 1999
).
Overexpression of murine CAR (mCAR) in HepG2 cells conferred PB
responsiveness on the endogenous CYP2B6 gene and
heterologous reporter gene constructs containing the CYP2B6
PB-responsive enhancer module (Sueyoshi et al., 1999
). In
mammalian cell lines and yeast, mCAR is transcriptionally active in the
absence of exogenous ligand (Forman et al., 1998
; Kawamoto et al.,
1999
; Sueyoshi et al., 1999
). The constitutive trans-activational capacity of mCAR is repressed by the
steroids androstanol (5
-androstan-3
-ol) and androstenol
(5
-androst-16-en-3
-ol) (Forman et al., 1998
). In HepG2 cells, the
ligand-dependent repression of mCAR is reversed by PB and PB-like
inducers (Kawamoto et al., 1999
; Sueyoshi et al., 1999
). More recently,
naturally occurring and xenobiotic mCAR and human CAR (hCAR) agonists
were identified (Moore et al., 2000
; Tzameli et al., 2000
). In
similarity to human and mouse PXR, hCAR and mCAR exhibited divergent
activation profiles (Lehmann et al., 1998
; Moore et al., 2000
).
In the liver and primary cultures of hepatocytes, mCAR is sequestered
in the cytoplasm and only translocates to the nucleus after exposure of
the cell to PB or PB-like inducers. The PB-induced nuclear
translocation is uncoupled by concomitant exposure to okadaic acid an
inhibitor of phosphatases 1 and 2A, suggesting that dephosphorylation
of mCAR is required for its nuclear compartmentalization (Kawamoto et
al., 1999
). Thus, the PB-induced dephosphorylation of CAR seems to be
critical step in CYP2B induction (Kawamoto et al., 1999
). In
support of this observation, previous reports have documented the
importance of phosphorylation status in CYP2B induction
(Sidhu and Omiecinski, 1995
; Nirodi et al., 1996
; Honkakoski and
Negishi, 1998
). Importantly, nuclear translocation of mCAR in HepG2
cells is spontaneous and does not seem to be dependent on ligand
binding and/or modification of phosphorylation status (Kawamoto et al.,
1999
; Sueyoshi et al., 1999
). Thus, cDNA-directed expression of mCAR
resulted in transcriptional activation of the endogenous
CYP2B6 gene in the absence of inducer. Moreover, although mCAR ligands, namely, androstanol and androstenol, inhibited the trans-activational capacity of mCAR in HepG2 cells they did
not block nuclear translocation of the protein (Sueyoshi et al., 1999
). Targeted in vivo disruption of mCAR completely abrogates PB and 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP)-mediated induction of the murine Cyp2b10 gene (Wei at al., 2000
),
demonstrating the pivotal role of this receptor in the xenobiotic
induction of some P450s. The mechanisms by which PB and PB-like
inducers modify the cellular localization of CAR seem to involve a
leucine-rich region near the C terminus of the CAR protein that has
been designated a xenochemical response signal (Zelko et al., 2001
).
Interestingly, mCAR-RXR
heterodimers are capable of binding the
prPXRE (bases
172 to
149) of the human CYP3A4 gene.
Additionally, a reporter gene construct containing multimerized copies
of this motif was transcriptionally activated by mCAR (Sueyoshi et al., 1999
; Tzameli et al., 2000
; Xie et al., 2000b
). Although
trans-activation of the native CYP3A4 promoter by
mCAR was not reported, the ability of both CAR-RXR
and PXR-RXR
heterodimers to interact with the same nuclear receptor-binding motif
in the CYP3A4 promoter suggests that interplay between
nuclear receptors is likely to be a significant factor in
CYP3A4 regulation. This contention is supported by the recent findings that hPXR can trans-activate the human
CYP2B6 gene (Goodwin et al., 2001
) and the mouse
Cyp2b10 gene (Xie et al., 2000b
) through response elements
that also interact with hCAR.
Accordingly, the present study was designed to investigate the role of
CAR in the transcriptional regulation of CYP3A4. CAR was
demonstrated to be capable of trans-activating
CYP3A4 expression. Moreover, hCAR-binding motifs in the
proximal promoter and distal enhancer regions of CYP3A4 were
mapped and shown to be identical to those described previously for hPXR
(Goodwin et al., 1999
).
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. The mammalian expression vector pSG5 and SuperScript II reverse transcriptase were from Stratagene (La Jolla, CA). PCR primers, TaqMan probes, and PCR master mix were sourced from Applied Biosystems (Foster City, CA). FuGENE 6 transfection reagent was provided by Roche Applied Science (Castle Hill, NSW, Australia).
Reporter Gene Constructs and Expression Vectors.
Preparation
of the chimeric CYP3A4-luciferase reporter gene constructs,
including the constructs containing mutated HREs, was described in
detail previously (Goodwin et al., 1999
). The structure of the p3A4-362
and p3A4-362(7836/7208ins) is shown in Fig.
1A. Site-directed mutagenesis of the
prPXRE in the CYP3A4 promoter (as shown in Fig. 3) was designed
to disrupt both the ER-6 motif as well as an overlapping imperfect DR-4
motif (AACTCAaaggAGGTCA). The hCAR and hRXR
expression vectors
pSG5-hCAR and pSG5-hRXR
, respectively, were generously provided by
Dr. Steven A. Kliewer (GlaxoSmithKline Research, Research Triangle
Park, NC).
|
Transient Transfection of Mammalian Cells.
The human
hepatoblastoma cell line HepG2 was obtained from the American Type
Culture Collection (Manassas, VA) and maintained in antibiotic-free
Dulbecco's modified Eagle's medium supplemented with 10%
heat-inactivated fetal calf serum. Cells (1 × 105) were inoculated into 24-well plates 24 h before transfection with FuGENE 6 (Roche Applied Science) according
to the manufacturer's instructions. Typically, cells were transfected
with 80 ng of luciferase reporter gene construct, 30 ng of
-galactosidase control vector (pCMV
), and 0 to 100 ng of receptor
expression vector (adjusted to 100 ng with pSG5). Subsequently, cells
were cultured for 48 h in fresh medium supplemented with 10%
charcoal-stripped serum. Luciferase activities were determined on cell
lysates using a commercially available system (Promega, Madison, WI).
-Galactosidase assays were performed as described previously (Foster
et al., 1988
).
Electrophoretic Mobility Shift Assay.
EMSA of putative
hCAR-hRXR
-binding motifs was performed using in vitro
transcribed/translated hCAR and hRXR
exactly as described previously
(Goodwin et al., 1999
).
Quantitation of CYP3A4 and PXR mRNA Levels.
CYP3A4 and hPXR
mRNA levels were examined by real-time reverse transcriptase-polymerase
chain reaction (RT-PCR). HepG2 cells were transfected in 60-mm-diameter
culture dishes, as described above, with the pSG5-hCAR expression
vector (0-1600 ng adjusted to 1600 ng with pSG5). The cells were
cultured for a further 48 h before extraction of RNA using a
commercially available reagent (TRIzol; Invitrogen, Carlsbad, CA). cDNA
was synthesized from 5 µg of total RNA using random hexamers and
Superscript II reverse transcriptase according to the manufacturer's
instructions. An aliquot of each cDNA synthesis reaction (1 µl) was
subjected to PCR amplification using a Prism 7700 real-time PCR
platform (Applied Biosystems). Primers and TaqMan probes were as
follows: CYP3A4 151 to 323 bp, forward primer
TTGTCCTACCATAAGGGCTTTTGT, reverse primer AAAGGCCTCCGGTTTGTGA, probe 210 to 238 bp FAM-AGTGTGGGGCTTTTATGATGGTCAACAGC-TAMRA; and hPXR 1448 to
1528 bp, forward primer CCCAGCCTGCTCATAGGTTC, reverse primer
GGGTGTGCTGAGCATTGATG, probe 1469 to 1497 bp
FAM-TGTTCCTGAAGATCATGGCTATGCTCACC-TAMRA. Results were normalized
against
-actin determined using a commercially available TaqMan kit
(catalog no. 401846; Applied Biosystems). Both the CYP3A4 and hPXR
probes were designed to cross intron-exon junctions to avoid
interference from genomic DNA. Moreover, the CYP3A4 primers and probe
were designed so as to exclude other CYP3As, particularly the highly
homologous CYP3A7 cDNA. Cycle parameters for all PCR were 50°C for 2 min then 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.
Trangenic Mice.
A transgene was constructed by linking the
CYP3A4 gene 5'-flanking region, extending from the
KpnI site at
13 kilobase pairs to +53 bp downstream of the
transcription start site, to an Escherichia coli
lacZ reporter gene. The latter comprises the coding region for the bacterial enzyme
-galactosidase flanked by DNA sequences for
eukaryotic translational start and stop signals, simian virus 40 transcriptional termination and polyadenylation signals, and an intron.
Mice carrying the CYP3A4/lacZ transgene were created by
microinjection of the DNA constructs into the pronuclei of zygotes
harvested from FVB/N strain mice. Microinjection and manipulation of
embryos were carried out by standard techniques (Hogan et al., 1994
).
Stable transgenic mouse lines were established by breeding from
transgenic founders identified by Southern analysis and the line used
for the present studies was termed CYP3A4-13kb-9/4. This transgenic
model will be described in detail elsewhere (G. R. Robertson, B. Goodwin, J. Field, C. Liddle, in preparation). Mice
(n = 3/group) were treated with 3 mg/kg TCPOBOP or
vehicle alone (corn oil) daily for 3 days by intraperitoneal injection as described previously (Wei at al., 2000
) before sacrifice on day 4.
-Galactosidase activity was visualized in cut sections of liver by
staining with
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside.
Statistics. Multiple comparisons were performed by factorial analysis of variance. Post hoc comparisons between categories were accomplished using the Bonferroni/Dunn test.
| |
Results |
|---|
|
|
|---|
The ability of hCAR to trans-activate the
CYP3A4 5'-flanking region was examined by transient
transfection of HepG2 cells. As shown in Fig. 1B, inset, the native
CYP3A4 proximal promoter (bases
362 to +53) did not confer
hCAR responsiveness on luciferase reporter gene expression. In
contrast, the p3A4-362(7836/7208ins) construct, which contains the XREM
region (bases
7836 to
7208) in addition to the proximal promoter,
was enhanced in a dose-dependent manner by cDNA-directed expression of
hCAR (Fig. 1B). Maximal induction of reporter gene expression
(approximately 8- to 10-fold) was observed with 25 to 100 ng of
pSG5-hCAR (Fig. 1B). Subsequent cotransfection experiments were
performed with 25 ng of pSG5-hCAR.
The interaction between hCAR-hRXR
heterodimers and putative nuclear
receptor-binding motifs located in the XREM and proximal promoter
regions of CYP3A4 was examined by EMSA using in
vitro-translated hCAR and hRXR
(Fig.
2). In keeping with previous reports
(Sueyoshi et al., 1999
), an everted repeat with a six-base spacer
(ER-6) within the proximal promoter known to bind hPXR-hRXR
heterodimers (prPXRE) complexed hCAR-hRXR
. Additionally, a direct
repeat with a three-base spacer (DR-3) within the XREM (dNR1) bound
hCAR-hRXR
with high affinity (Fig. 2B). Extended autoradiography
revealed that additional motifs within the XREM, referred to as dNR2
and dNR3 (Fig. 2A), were capable of weakly complexing hCAR-hRXR
heterodimers (data not shown). Importantly, the affinity of dNR2 and
dNR3 for hCAR-hRXR
was substantially lower than either dNR1 or
prPXRE (Fig. 2, B and C; data not shown).
|
The relative affinity of prPXRE, dNR1, and dNR2 for hCAR-hRXR
was
examined by competition binding studies. A 5-fold molar excess of
unlabeled dNR1 effectively competed with
32P-labeled prPXRE for hCAR-hRXR
(Fig. 2C).
Indeed, these competition-binding studies indicated that the affinity
of dNR1 for hCAR-hRXR
was approximately 4- to 5-fold higher than
that of prPXRE. Thus, CAR-RXR
heterodimers exhibit higher affinity
for DR-3 than ER-6 elements. In support of this observation, the
intensity of the band-shift resulting from complexation of hCAR-hRXR
with dNR1 was significantly stronger than that seen when prPXRE was
used as a probe (Fig. 2B). In comparison, a 200-fold molar excess of
unlabeled dNR2 failed to effectively compete with prPXRE for
hCAR-hRXR
binding (Fig. 2C).
The relative contribution of the two high-affinity hCAR-hRXR
-binding
motifs, dNR1 and prPXRE, to the hCAR-mediated
trans-activation of p3A4-362(7836/7208ins) was examined by
site-directed mutagenesis. Cotransfection of pSG5-hCAR and
p3A4-362(7836/7208ins) resulted in an 8- to 9-fold induction in
reporter gene activity (Fig. 3). Mutation
of dNR1 in the context of this construct resulted in a 56% reduction
in hCAR responsiveness. Thus, cotransfection of pSG5-hCAR and the
p3A4-362(7836/7208ins) construct harboring a mutated dNR1 site resulted
in a 4-fold increase in luciferase expression. Similarly, mutation of
prPXRE decreased hCAR-mediated trans-activation by
approximately 45% (5-fold induction). Although the prPXRE in the
context of the p3A4-362 construct (Fig. 1B, inset) has no inherent
ability to confer hCAR inducibility on the luciferase reporter gene,
this element seems to cooperatively interact with elements within the
XREM region. This functional cooperativity was further investigated by
linking the XREM region to a minimal thymidine kinase promoter (
105
to +52 bp). The presence of the heterologous promoter completely
abrogated hCAR-mediated expression (data not shown), in contrast to the
partial loss of expression seen when the prPXRE alone was mutated.
Mutation of both dNR1 and prPXRE removed approximately 85% of the
wild-type hCAR responsiveness. The residual hCAR inducibility
(1.5-fold) of this construct is most probably mediated by the
low-affinity hCAR-hRXR
-binding motifs described above, namely, dNR2
and dNR3. These data are summarized in Fig. 3.
|
In HepG2 cells, exogenously expressed mCAR is known to spontaneously
translocate to the nucleus. In this system, nuclear
compartmentalization of the receptor and trans-activation of
target genes are ligand-independent. Therefore, we examined the ability
of hCAR to regulate expression of the endogenous CYP3A4 gene
in HepG2 cells, a cell line that has been reported not to express
significant amounts of CYP3A4 mRNA or protein. Using the sensitive
technique of real-time RT-PCR CYP3A4-specific transcripts
were routinely detected in HepG2 cells. Transient transfection of HepG2
cells with the hCAR expression vector pSG5-hCAR resulted in a
dose-dependent increase in CYP3A4 mRNA levels (Fig.
4A). To exclude the possibility that the
hCAR-induced increase in CYP3A4 mRNA was secondary to induction of hPXR
expression, the abundance of hPXR mRNA was also determined by real-time
RT-PCR. No increase in hPXR expression was observed (Fig. 4B).
|
To provide additional evidence for a functional role for CAR in
CYP3A4 regulation, mice bearing a transgene consisting of the CYP3A4 5'-flanking region (
13 kb to +53 bp) linked to
a
-galactosidase reporter gene were treated with the mCAR-specific
ligand TCPOBOP or vehicle (n = 3/group), as described
under Experimental Procedures. In mice receiving vehicle
alone reporter gene expression was restricted to a small number of
hepatocytes immediately adjacent to central veins or larger hepatic
veins. In contrast, mice treated with TCPOBOP exhibited a striking
induction of hepatic reporter gene expression, extending outward from
central veins, such that approximately one-third of all hepatocytes
exhibited positive staining for
-galactosidase (Fig.
5). Identical results were obtained for
all three animals within each group.
|
| |
Discussion |
|---|
|
|
|---|
The recognition that nuclear receptors capable of recognizing a
range of lipophilic xenobiotic and endobiotic ligands can in turn
regulate metabolizing and transporting genes has provided a new
paradigm to explain how an organism is able to mount an adaptive
response to potentially toxic compounds. The most extensively studied
receptor in this respect is the PXR, although it is clear that there is
substantial overlap between the ligand specificities of PXR and CAR
(Moore et al., 2000
). CYP3A4 represents a major pathway for clearance
of both xenobiotics and endobiotics, and it is clear that PXR is a
major mediator of transcriptional induction of this enzyme. To date,
however, it is has been uncertain whether CAR is also able to
trans-activate this enzyme in response to xenobiotic challenge.
In the present study we have shown that hCAR is capable of interacting
with the regulatory 5'-flanking region of the CYP3A4 gene.
Recent reports suggested that the prPXRE of CYP3A4, an
everted repeat of the AG(G/T)TCA hexamer separated by six nucleotides (ER-6), was capable of conferring CAR responsiveness on a heterologous thymidine kinase promoter (Sueyoshi et al., 1999
; Tzameli et al., 2000
). However, in the present study this element, in the context of
the native CYP3A4 promoter (bases
362 to +53), did not
confer hCAR responsiveness in transient transfection studies performed in HepG2 cells. Similar observations have been made for the
hPXR-mediated trans-activation of CYP3A4-reporter
gene constructs (Goodwin et al., 1999
). The ability of hCAR-RXR
and
hPXR-RXR
heterodimers to interact with common nuclear
receptor-binding motifs (Sueyoshi et al., 1999
; Tzameli et al., 2000
)
suggested that the PXR-responsive XREM region of CYP3A4
(bases
7836 to
7208) may also be capable of mediating
trans-activation of CYP3A4 by hCAR. Indeed, when the XREM region was linked to the proximal promoter, a CAR-dependent increase in reporter gene expression was observed.
To further understand the nature of the interaction between hCAR and
CYP3A4, EMSA was performed on putative response elements within the proximal promoter and XREM. As described previously (Sueyoshi et al., 1999
), the prPXRE complexed hCAR-hRXR
heterodimers. Additionally, there was a high-affinity site within the
XREM, denoted as dNR1, that also bound hCAR-hRXR
. Importantly, the DNA binding profile of hCAR-hRXR
delineated in this study was highly
homologous to that of hPXR-hRXR
(Goodwin et al., 1999
). The
importance of these DNA motifs in CAR-directed gene expression was
confirmed by site-directed mutagenesis. Importantly, mutagenesis experiments revealed cooperation between dNR1 and the prPXRE, mirroring
what we have observed previously for the PXR (Goodwin et al., 1999
).
This is despite our finding that the prPXRE alone lacks the ability to
mediate CAR-directed gene expression. To further examine this, the
CYP3A4 proximal promoter was replaced with a heterologous
minimal thymidine kinase promoter. Surprisingly, all CAR-mediated
transcription was lost, despite the presence of the XREM. This
demonstrates that there is a functional dependence of the XREM on the
native promoter that is independent of the prPXRE.
To determine the functional relevance of the interaction between CAR
and CYP3A4, we used two entirely different models. First, we sought to
determine whether hCAR was capable of regulating the endogenous
CYP3A4 gene in HepG2 cells. In this cell line exogenously expressed mCAR is known to spontaneously translocate to the nucleus and
activate expression of the PB-inducible CYP2B6 gene
(Sueyoshi et al., 1999
). In this system, nuclear compartmentalization
of the receptor and trans-activation of the target gene are
inducer-independent (Kawamoto et al., 1999
; Sueyoshi et al., 1999
).
Transient transfection of hCAR resulted in a significant increase in
endogenous CYP3A4 mRNA expression. Moreover, this was not mediated by
an indirect effect of hCAR on endogenous PXR expression. These data
demonstrate that endogenous CYP3A4 gene in HepG2 cells is
sensitive to hCAR-mediated regulation. Second, we performed a
functional in vivo experiment. We were able to take advantage of the
observation that the PB-like inducer TCPOBOP is a selective ligand for
mCAR and does not bind to or activate mPXR (Moore et al., 2000
). There
is a lack of a similarly selective ligand for hCAR, making experiments
performed in human models, such as primary human hepatocytes, difficult to interpret. Thus, mice carrying a CYP3A4 regulatory
transgene provide a useful system to determine the ability of CAR to
trans-activate CYP3A4. The finding that TCPOBOP
was able to markedly induce hepatic expression of the transgene
provides strong evidence in favor of a functional role for CAR in
CYP3A4 regulation.
In the mouse, induction of Cyp2b gene expression by a range
of xenochemicals, including PB, is mediated by CAR. Targeted disruption of the CAR gene completely abrogates Cyp2b10 induction by PB
and TCPOBOP (Wei et al., 2000
). In contrast, disruption of the murine PXR gene does not affect PB induction of Cyp3a11, indicating
that in the mouse CAR is capable of mediating the inductive response of
CYP3A genes to PB as well (Staudinger et al., 2001
). Given that hCAR is capable of trans-activating the human
CYP2B6 gene in response to PB and PB-like inducers (Sueyoshi
et al., 1999
), it would be reasonable to assume that CYP3A4
and CYP2B6 would be coordinately regulated on exposure of
the hepatocyte to compounds that activate hCAR. Induction of both
CYP3A4 and CYP2B6 expression by PB is well
documented (Pichard et al., 1990
; Schuetz et al., 1993
; Kocarek et al.,
1995
; Chang et al., 1997
; Gervot et al., 1999
; Sueyoshi et al., 1999
).
Additionally, the few bone fide CYP2B6 inducers identified
to date, including TCPOBOP (Smith et al., 1993
) and cyclophosphamide
(Chang et al., 1997
; Gervot et al., 1999
), also up-regulate
CYP3A4 expression. Evidently, induction of multiple P450
genes upon exposure to potentially toxic or carcinogenic compounds
increases the probability that the organism can successfully metabolize
and ultimately excrete xenobiotics.
Goodwin et al. (2001)
have shown that both hPXR and hCAR can mediate
the PB induction of the CYP2B6 gene in primary human hepatocytes, although hCAR predominates in this respect. It seems likely that the conformation of the HREs in the target genes is the
main determinant as to which nuclear receptor predominates. In
CYP2B6 there are two adjacent DR-4 motifs, separated by only 16 base pairs (Sueyoshi et al., 1999
). In contrast, in the
CYP3A4 gene the two predominant PXR/CAR binding motifs are
separated by in excess of 7.5 kilobase pairs, an arrangement that seems to favor PXR-mediated induction over CAR (Goodwin et al., 1999
, 2001
).
In summary, CAR was shown to directly regulate the transcriptional
activity of the CYP3A4 gene, both in vitro and in vivo. trans-Activation of CYP3A4 by CAR was mediated by
nuclear receptor-binding motifs located in the distal XREM and promoter
proximal regions of the gene. These elements are capable of binding
both hCAR-hRXR
and hPXR-hRXR
heterodimers with high affinity. The
convergence of hCAR- and hPXR-mediated signaling pathways at common
response elements in the CYP3A4 gene clearly demonstrates
that cross talk between these two nuclear receptors is probably an
important factor in the regulation of this gene. Furthermore, the
ability of CAR and PXR to regulate the same gene suggests that these
proteins are integral parts of common homeostatic pathways.
| |
Footnotes |
|---|
Received December 19, 2001; Accepted May 2, 2002
1 Current address: Nuclear Receptor Systems Research, GlaxoSmithKline Inc., Five Moore Dr., Research Triangle Park, NC 27709-3398.
This work was supported by a project grant from the National Health and Medical Research Council of Australia. B.G. is the recipient of a National Health and Medical Research Council of Australia Dora Lush Postgraduate Research Scholarship.
Address correspondence to: C. Liddle, Department of Clinical Pharmacology, Westmead Hospital, Westmead, NSW, 2145 Australia. E-mail: chris_liddle{at}wmi.usyd.edu.au
| |
Abbreviations |
|---|
P450, cytochrome P450;
PB, phenobarbital;
hPXR, human pregnane X receptor;
PXR, pregnane X receptor;
HRE, hormone
response element;
RXR
, 9-cis retinoic acid
receptor-
;
prPXRE, proximal pregnane X receptor response element;
XREM, xenobiotic-responsive enhancer module;
CAR, constitutive
androstane receptor;
mCAR, murine constitutive androstane receptor;
hCAR, human constitutive androstane receptor;
TCPOBOP, 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene;
PCR, polymerase chain
reaction;
EMSA, electrophoretic mobility shift assay;
kb, kilobase;
RT-PCR, reverse transcriptase-polymerase chain reaction;
bp, base pair(s).
| |
References |
|---|
|
|
|---|
.
Nature (Lond)
395:
612-615[CrossRef][Medline].This article has been cited by other articles:
![]() |
J. M. Phillips, L. D. Burgoon, and J. I. Goodman Phenobarbital Elicits Unique, Early Changes in the Expression of Hepatic Genes that Affect Critical Pathways in Tumor-Prone B6C3F1 Mice Toxicol. Sci., June 1, 2009; 109(2): 193 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sandanaraj, S. Lal, V. Selvarajan, L. L. Ooi, Z. W. Wong, N. S. Wong, P. C. S. Ang, E. J.D. Lee, and B. Chowbay PXR Pharmacogenetics: Association of Haplotypes with Hepatic CYP3A4 and ABCB1 Messenger RNA Expression and Doxorubicin Clearance in Asian Breast Cancer Patients Clin. Cancer Res., November 1, 2008; 14(21): 7116 - 7126. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsubara, K. Yoshinari, K. Aoyama, M. Sugawara, Y. Sekiya, K. Nagata, and Y. Yamazoe Role of Vitamin D Receptor in the Lithocholic Acid-Mediated CYP3A Induction in Vitro and in Vivo Drug Metab. Dispos., October 1, 2008; 36(10): 2058 - 2063. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Masson, M. Qatanani, A. L. Sberna, R. Xiao, J. P. Pais de Barros, J. Grober, V. Deckert, A. Athias, P. Gambert, L. Lagrost, et al. Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice J. Lipid Res., August 1, 2008; 49(8): 1682 - 1691. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gupta, G. M. Mugundu, P. B. Desai, K. E. Thummel, and J. D. Unadkat Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors Drug Metab. Dispos., June 1, 2008; 36(6): 1172 - 1180. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Biggs, J. Wan, N. S. Cutler, J. Hakkola, P. Uusimaki, H. Raunio, and G. S. Yost Transcription Factor Binding to a Putative Double E-Box Motif Represses CYP3A4 Expression in Human Lung Cells Mol. Pharmacol., September 1, 2007; 72(3): 514 - 525. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cerveny, L. Svecova, E. Anzenbacherova, R. Vrzal, F. Staud, Z. Dvorak, J. Ulrichova, P. Anzenbacher, and P. Pavek Valproic Acid Induces CYP3A4 and MDR1 Gene Expression by Activation of Constitutive Androstane Receptor and Pregnane X Receptor Pathways Drug Metab. Dispos., July 1, 2007; 35(7): 1032 - 1041. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsubara, W. Noracharttiyapot, T. Toriyabe, K. Yoshinari, K. Nagata, and Y. Yamazoe Assessment of Human Pregnane X Receptor Involvement in Pesticide-Mediated Activation of CYP3A4 Gene Drug Metab. Dispos., May 1, 2007; 35(5): 728 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Urquhart, R. G. Tirona, and R. B. Kim Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs J. Clin. Pharmacol., May 1, 2007; 47(5): 566 - 578. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Auerbach, J. G. DeKeyser, M. A. Stoner, and C. J. Omiecinski CAR2 Displays Unique Ligand Binding and RXR{alpha} Heterodimerization Characteristics Drug Metab. Dispos., March 1, 2007; 35(3): 428 - 439. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Jackson, S. S. Ferguson, M. Negishi, and J. A. Goldstein Phenytoin Induction of the Cyp2c37 Gene Is Mediated by the Constitutive Androstane Receptor Drug Metab. Dispos., December 1, 2006; 34(12): 2003 - 2010. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sakai, H. Iwata, E.-Y. Kim, O. Tsydenova, N. Miyazaki, E. A. Petrov, V. B. Batoev, and S. Tanabe Constitutive Androstane Receptor (CAR) as a Potential Sensing Biomarker of Persistent Organic Pollutants (POPs) in Aquatic Mammal: Molecular Characterization, Expression Level, and Ligand Profiling in Baikal Seal (Pusa sibirica) Toxicol. Sci., November 1, 2006; 94(1): 57 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. He, M. H. Court, D. J. Greenblatt, and L. L. von Moltke Human Pregnane X Receptor: Genetic Polymorphisms, Alternative mRNA Splice Variants, and Cytochrome P450 3A Metabolic Activity. J. Clin. Pharmacol., November 1, 2006; 46(11): 1356 - 1369. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Faucette, T. Sueyoshi, C. M. Smith, M. Negishi, E. L. LeCluyse, and H. Wang Differential Regulation of Hepatic CYP2B6 and CYP3A4 Genes by Constitutive Androstane Receptor but Not Pregnane X Receptor J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1200 - 1209. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Auerbach, M. A. Stoner, S. Su, and C. J. Omiecinski Retinoid X Receptor-{alpha}-Dependent Transactivation by a Naturally Occurring Structural Variant of Human Constitutive Androstane Receptor (NR1I3) Mol. Pharmacol., November 1, 2005; 68(5): 1239 - 1253. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Sadee and Z. Dai Pharmacogenetics/genomics and personalized medicine Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R207 - R214. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Noreault, V. E. Kostrubsky, S. G. Wood, R. C. Nichols, S. C. Strom, H. W. Trask, S. A. Wrighton, R. M. Evans, J. M. Jacobs, P. R. Sinclair, et al. ARSENITE DECREASES CYP3A4 AND RXR{alpha} IN PRIMARY HUMAN HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 993 - 1003. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Choi, S. Lee, S.-Y. Yeom, G. H. Kim, J. W. Lee, and S.-W. Kim Characterization of Activating Signal Cointegrator-2 as a Novel Transcriptional Coactivator of the Xenobiotic Nuclear Receptor Constitutive Androstane Receptor Mol. Endocrinol., July 1, 2005; 19(7): 1711 - 1719. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Martinez-Jimenez, M. J. Gomez-Lechon, J. V. Castell, and R. Jover Transcriptional Regulation of the Human Hepatic CYP3A4: Identification of a New Distal Enhancer Region Responsive to CCAAT/Enhancer-Binding Protein {beta} Isoforms (Liver Activating Protein and Liver Inhibitory Protein) Mol. Pharmacol., June 1, 2005; 67(6): 2088 - 2101. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cheung, A.-M. Yu, J. M. Ward, K. W. Krausz, T. E. Akiyama, L. Feigenbaum, and F. J. Gonzalez THE CYP2E1-HUMANIZED TRANSGENIC MOUSE: ROLE OF CYP2E1 IN ACETAMINOPHEN HEPATOTOXICITY Drug Metab. Dispos., March 1, 2005; 33(3): 449 - 457. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Qatanani, J. Zhang, and D. D. Moore Role of the Constitutive Androstane Receptor in Xenobiotic-Induced Thyroid Hormone Metabolism Endocrinology, March 1, 2005; 146(3): 995 - 1002. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. M. Stedman, C. Liddle, S. A. Coulter, J. Sonoda, J. G. A. Alvarez, D. D. Moore, R. M. Evans, and M. Downes Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury PNAS, February 8, 2005; 102(6): 2063 - 2068. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Jackson, S. S. Ferguson, R. Moore, M. Negishi, and J. A. Goldstein The Constitutive Active/Androstane Receptor Regulates Phenytoin Induction of Cyp2c29 Mol. Pharmacol., June 1, 2004; 65(6): 1397 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Jinno, T. Tanaka-Kagawa, N. Hanioka, S. Ishida, M. Saeki, A. Soyama, M. Itoda, T. Nishimura, Y. Saito, S. Ozawa, et al. Identification of Novel Alternative Splice Variants of Human Constitutive Androstane Receptor and Characterization of Their Expression in the Liver Mol. Pharmacol., March 1, 2004; 65(3): 496 - 502. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Matsumura, T. Saito, Y. Takahashi, T. Ozeki, K. Kiyotani, M. Fujieda, H. Yamazaki, H. Kunitoh, and T. Kamataki Identification of a Novel Polymorphic Enhancer of the Human CYP3A4 Gene Mol. Pharmacol., February 1, 2004; 65(2): 326 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Handschin and U. A. Meyer Induction of Drug Metabolism: The Role of Nuclear Receptors Pharmacol. Rev., December 1, 2003; 55(4): 649 - 673. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, S. S. Ferguson, M. Negishi, and J. A. Goldstein Identification of Constitutive Androstane Receptor and Glucocorticoid Receptor Binding Sites in the CYP2C19 Promoter Mol. Pharmacol., August 1, 2003; 64(2): 316 - 324. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. R. Robertson, J. Field, B. Goodwin, S. Bierach, M. Tran, A. Lehnert, and C. Liddle Transgenic Mouse Models of Human CYP3A4 Gene Regulation Mol. Pharmacol., July 1, 2003; 64(1): 42 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Auerbach, R. Ramsden, M. A. Stoner, C. Verlinde, C. Hassett, and C. J. Omiecinski Alternatively spliced isoforms of the human constitutive androstane receptor Nucleic Acids Res., June 15, 2003; 31(12): 3194 - 3207. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Maglich, D. J. Parks, L. B. Moore, J. L. Collins, B. Goodwin, A. N. Billin, C. A. Stoltz, S. A. Kliewer, M. H. Lambert, T. M. Willson, et al. Identification of a Novel Human Constitutive Androstane Receptor (CAR) Agonist and Its Use in the Identification of CAR Target Genes J. Biol. Chem., May 2, 2003; 278(19): 17277 - 17283. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Staudinger, A. Madan, K. M. Carol, and A. Parkinson Regulation of Drug Transporter Gene Expression by Nuclear Receptors Drug Metab. Dispos., May 1, 2003; 31(5): 523 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, S. Faucette, T. Sueyoshi, R. Moore, S. Ferguson, M. Negishi, and E. L. LeCluyse A Novel Distal Enhancer Module Regulated by Pregnane X Receptor/Constitutive Androstane Receptor Is Essential for the Maximal Induction of CYP2B6 Gene Expression J. Biol. Chem., April 11, 2003; 278(16): 14146 - 14152. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||